Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.68 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12866125 | 1.00 | RAB9A (0.69) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL12884278 | 0.85 | RAB9A (0.73) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL29230091 | 0.84 | KDM4E (0.61) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL29230090 | 0.84 | KDM4E (0.61) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL31522348 | 0.83 | RAB9A (0.71) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL28433887 | 0.83 | GLA (0.78) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL10036065 | 0.83 | GLA (0.78) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL28433890 | 0.83 | GLA (0.78) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL11062170 | 0.83 | GLA (0.78) | RAB9AKDM4ENPC1MAPTMEN1 | |
| SCHEMBL12894580 | 0.83 | CYSLTR2 (0.68) | RAB9AKDM4ENPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | claimed |
| US-6670377-B1 | Inhibitory properties of human immunodeficiency virus integrase | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2003-12-30 | — | — | US | claimed |
| EP-0975597-B1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NAT RECH SCIENT (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | disclosed |
| WO-2006129134-A1 | SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS | BIOALLIANCE PHARMA (FR) | 2006-12-07 | — | — | WO | disclosed |
| US-6670377-B1 | Inhibitory properties of human immunodeficiency virus integrase | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2003-12-30 | — | — | US | disclosed |
| EP-0975597-A1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998045269-A1 | QUINOLINE DERIVATIVES, HAVING IN PARTICULAR ANTIVIRAL PROPERTIES, PREPARATION AND BIOLOGICAL APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CTSL, CDKL1, QTRT2 | RAB9A 2746/4885KDM4E 2169/4885NPC1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.